Loading clinical trials...
Loading clinical trials...
A Primary Vaccination Study to Assess the Immunogenicity, Safety & Reactogenicity of 1 Dose of 4 Different Formulations of GSK Biologicals' Meningococcal Conjugate Vaccine (MenACWY) vs 1 Dose of MENCEVAX™ ACWY in Healthy Subjects Aged 15-19 Years
Conditions
Interventions
Meningococcal Vaccine
Locations
1
Denmark
GSK Investigational Site
Aarhus N, Denmark
Start Date
August 1, 2005
Completion Date
October 1, 2005
Last Updated
September 21, 2016
NCT04886154
NCT01962207
NCT00508261
NCT01755689
NCT00974363
NCT00126984
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions